Recent Posts
News•Feb 25, 2026
Male Infertility Care to Shift Treatment Burden From Women
Infertility has long been framed as a women's issue, yet about half of cases stem from male factors. New treatments such as Igyxos' IGX12 monoclonal antibody, which enhances follicle‑stimulating hormone activity, aim to improve sperm production and reduce the physical burden on women during IVF. Phase 1 trials demonstrated safety, and a €5.7 million French grant will support upcoming Phase 2 studies across Europe. Parallel efforts—including in‑vitro spermatogenesis, leflutrozole, and mRNA‑based gene therapy—signal a broader shift toward male‑focused fertility solutions.
By Labiotech.eu
News•Feb 24, 2026
Pfizer’s Strategy: How the Company Is Evolving After Its COVID Success
Pfizer’s post‑COVID strategy pivots from vaccine and antiviral sales to rebuilding growth through oncology and metabolic assets. The 2026 guidance excludes COVID revenue, projects modest 4% operational growth, and anticipates a $1.5 billion patent‑cliff hit. To offset these pressures, Pfizer completed...
By Labiotech.eu
News•Feb 23, 2026
Six RNAi Companies to Keep an Eye on in 2026
RNA interference (RNAi) has moved from a scientific curiosity to a fast‑growing therapeutic platform, with the global market projected to reach $1.97 billion by 2032. Six biotech firms—Aerska, ADARx, Alnylam, Arrowhead, City Therapeutics and SanegeneBio—are leading the next wave of innovation...
By Labiotech.eu
News•Feb 20, 2026
Inside Oxford’s Biotech Hub: A Scientific Powerhouse Situated in the U.K.’s Golden Triangle
Oxford has cemented its status as a leading European biotech hub, anchored by the University of Oxford’s deep biomedical expertise and a thriving spin‑out ecosystem. The Oxford Science Park now houses nearly 100 life‑science companies, while the £1.2 bn Oxford North...
By Labiotech.eu
News•Feb 20, 2026
Accelerating Rare Disease Cures with ASOs, Gene Editing, and AI
Professor Matthew Wood, Oxford’s leading neuroscientist, heads the Oxford‑Harrington Rare Disease Centre, a partnership designed to fast‑track therapies for rare neuromuscular and genetic disorders. He outlines a vision to make antisense oligonucleotides (ASOs) and gene‑editing tools more modular, scalable, and...
By Labiotech.eu
News•Feb 18, 2026
Innovation in Ophthalmology: How Biotechs Are Reshaping the Treatment of Eye Diseases
Vision loss remains a leading disability, prompting biotech firms to shift from symptom‑management to disease‑modifying therapies. Gene‑replacement approaches using AAV vectors dominate the inherited retinal disease pipeline, highlighted by Luxturna’s success and multiple late‑stage candidates such as Beacon’s laru‑zova and...
By Labiotech.eu
News•Feb 18, 2026
Six Biotechs to Know in Barcelona
Barcelona is emerging as a premier European life‑sciences hub, contributing 7.6 % of Catalonia’s GDP and ranking sixth in scientific output. Six local biotech firms—Accure Therapeutics, Oryzon Genomics, SpliceBio, Peptomyc, Ona Therapeutics and Integra Therapeutics—are advancing diverse modalities from small‑molecule neuroprotectors...
By Labiotech.eu
News•Feb 17, 2026
Can Treg Cell Therapy Really Target Autoimmunity?
Regulatory T‑cell (Treg) therapies are moving from discovery to clinic, with multiple biotech firms reporting early clinical data. Sonoma Biotherapeutics’ CAR‑Treg candidate SBT‑77‑7101 achieved a 67% reduction in rheumatoid‑arthritis swelling in a Phase 1 trial, while Coya Therapeutics secured IND approval...
By Labiotech.eu
News•Feb 13, 2026
Using AI to Crack Undruggable Drug Targets
ProPhet, an Israeli AI‑driven startup founded in late 2024, leverages a novel machine‑learning platform that projects proteins and small molecules into a common interaction space. This approach allows the company to screen billions of compounds against targets previously deemed undruggable,...
By Labiotech.eu
News•Feb 11, 2026
Seven Influential Women in Biotech in 2026
The article spotlights seven women reshaping biotech in 2026, from Shehnaaz Suliman’s $29 million‑funded mRNA program at ReCode to Julie Kim’s historic appointment as Takeda’s first female CEO. It details their strategic wins—such as Vertex’s CRISPR therapy approval under Reshma Kewalramani...
By Labiotech.eu
News•Feb 11, 2026
Eight Biotech Companies Spearheading the Antibody Drug Conjugate New Wave
A new wave of eight biotech firms is redefining antibody‑drug conjugates (ADCs) by pursuing unconventional targets, advanced linker chemistries, and novel cytotoxic payloads. Companies such as Adcendo, Adcentrx, and Tubulis are advancing phase 1/2 programs that address sarcoma, Nectin‑4, NaPi2b, and...
By Labiotech.eu
News•Feb 10, 2026
Astellas’ “Strategic Brands” And “Primary Focuses” After XTANDI
Astellas is reshaping its portfolio as XTANDI nears patent expiry, shifting from a single‑product reliance to a set of “strategic brands.” The company is promoting approved assets such as PADCEV, VYLOY, VEOZAH and IZERVAY to smooth revenue across oncology, menopause...
By Labiotech.eu
News•Feb 9, 2026
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
The breast‑cancer pipeline is heating up as several late‑stage candidates demonstrate significant efficacy across sub‑types. Roche’s oral SERD giredestrant cut invasive disease recurrence by 30% in early‑stage ER‑positive patients, while AstraZeneca’s camizestrant combined with a CDK4/6 inhibitor reduced progression risk...
By Labiotech.eu
News•Feb 6, 2026
Top Biotech Deals in January 2026
January 2026 saw a slowdown in headline biopharma M&A, yet the deals that closed were strategically sizable. Amgen bought Dark Blue Therapeutics for $840 million, adding an AML protein‑degrader, while GSK acquired RAPT Therapeutics for $2.2 billion to expand its anti‑IgE portfolio....
By Labiotech.eu
News•Feb 6, 2026
How Eli Lilly’s Biotech Collaboration Model Is Rewriting Early-Stage Innovation
Eli Lilly’s ExploR&D program redefines pharma‑biotech partnerships by offering early‑stage companies shared‑risk, full‑stack R&D support. The model integrates Lilly’s discovery, chemistry, and clinical teams to accelerate the journey from molecule creation to proof‑of‑concept, especially in a tightening funding environment. It focuses...
By Labiotech.eu
Deals•Jan 8, 2026
Swiss Biotech TECregen Raises $12.56M Seed Round Led by Boehringer Ingelheim Venture Fund
Swiss biotech TECregen announced a CHF 10 million ($12.56 million) seed round, led by Boehringer Ingelheim Venture Fund, to develop thymus‑regenerating biologics. The funding will support the company’s engineered “thymopoietics” platform aimed at rejuvenating thymic epithelial cells.
Labiotech.eu